Zobrazeno 1 - 10
of 150
pro vyhledávání: '"M. S. Hirsch"'
Publikováno v:
WHO/IARC Classification of Tumours; 2022, Vol. 8, p87-89, 3p
Publikováno v:
Journal of Virology. 70:7725-7733
Disseminated cytomegalovirus (CMV) infection is a frequent occurrence in human immunodeficiency virus-infected humans and in simian immunodeficiency virus (SIV)-infected rhesus macaques. Rhesus macaques are a suitable animal model with which to study
Autor:
W D Hardy, Mohan Beltangady, Margaret A. Fischl, S. H. Liou, Raphael Dolin, Michael J. Brown, Carla Pettinelli, David A. Amato, Anne Cross, M. S. Hirsch
Publikováno v:
Archives of Internal Medicine. 155:961-974
BACKGROUND We conducted a trial to compare treatment with zidovudine or didanosine in patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who had received little or no previous therapy with zidovudine. METHODS Six hundred sev
Autor:
Richard T. D'Aquila, Debra P. Merrill, M. S. Hirsch, T. Mazzulli, Stefano Rusconi, Majaz Moonis, Ting-Chao Chou
Publikováno v:
Antimicrobial Agents and Chemotherapy. 38:656-661
We compared the in vitro efficacies of two-, three-, and four-drug combinations given continuously or in alternating regimens against a clinical isolate of human immunodeficiency virus type 1. In H9 cells and peripheral blood mononuclear cells, at th
Publikováno v:
Antimicrobial Agents and Chemotherapy. 36:1559-1562
The combination of zidovudine (AZT) and 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 (HIV-1) replication in vitro with AZT-sensitive and AZT-resistant clinical isolates and HIV-1IIIB. Synergy was determined by th
Publikováno v:
WHO/IARC Classification of Tumours; 2022, Vol. 8, p92-93, 2p
Autor:
M S Osburne, P V Pallai, Majaz Moonis, S K Singh, K J Willis, Edith A. Neidhardt, J C Jenson, A T Profy, M. S. Hirsch, Stefano Rusconi, Debra P. Merrill
Publikováno v:
Scopus-Elsevier
PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that bind to CD4 with nanomolar affinity and block binding of gp120. Both have activity against human immunodeficiency virus type 1 in H9 cells, peripheral blood mononuclear cells, and primary
Autor:
Adriana Weinberg, Michelle A. Kendall, Alejo Erice, M. S. Hirsch, Bruce Polsky, Courtney N. Tierney, Angela M. Caliendo
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 37(4)
We undertook a prospective study to analyze cytomegalovirus (CMV) end-organ disease (EOD) in subjects with advanced human immunodeficiency virus (HIV) infection. Of 403 individuals without prior CMV EOD who were followed up for a median of 151 weeks,
Publikováno v:
Antiviral therapy. 4(1)
Can aggressive anti-human immunodeficiency virus (HIV) induction regimens be simplified after sufficient virus suppression is achieved? In vitro studies were conducted to evaluate the hypothesis that aggressive induction regimens could be followed by
Autor:
X J, Zhou, L B, Sheiner, R T, D'Aquila, M D, Hughes, M S, Hirsch, M A, Fischl, V A, Johnson, M, Myers, J P, Sommadossi
Publikováno v:
Antimicrobial agents and chemotherapy. 43(1)
The population pharmacokinetics of nevirapine (NVP), zidovudine (ZDV), and didanosine (ddI) were evaluated in a total of 175 patients infected with human immunodeficiency virus randomized to receive either a double combination of ZDV plus ddI or a tr